Inozyme Company

Inozyme is a provider of therapies for rare diseases of calcification affecting soft tissues and bone created to offer potentially disease-modifying therapies to help children who are affected with rare, but severe and debilitating disorders of metabolism. The company's enzyme replacement therapy provides the treatment of Generalized Arterial Calcification of Infancy (GACI) and Autosomal Recessive Hypophosphatemic Rickets Type 2 (ARHR2), enabling patients to treat diseases characterized by mineral imbalances in the body.

Founded Date: 2016-01-01
Technology: Data-driven Technologies
Funding Status: IPO
Total Funding: 150099989
Employee Number: 11-50
Headquarters: Boston, Massachusetts, United States
Investors Number: 9
Last Funding Type: Series A
Estimated Revenue: $10M to $50M
Industry: Gene therapy